1. Home
  2. SPRO vs OMCC Comparison

SPRO vs OMCC Comparison

Compare SPRO & OMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • OMCC
  • Stock Information
  • Founded
  • SPRO 2013
  • OMCC 1985
  • Country
  • SPRO United States
  • OMCC United States
  • Employees
  • SPRO N/A
  • OMCC N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • OMCC
  • Sector
  • SPRO Health Care
  • OMCC
  • Exchange
  • SPRO Nasdaq
  • OMCC NYSE
  • Market Cap
  • SPRO 45.7M
  • OMCC 40.0M
  • IPO Year
  • SPRO 2017
  • OMCC N/A
  • Fundamental
  • Price
  • SPRO $0.75
  • OMCC $5.94
  • Analyst Decision
  • SPRO Buy
  • OMCC
  • Analyst Count
  • SPRO 4
  • OMCC 0
  • Target Price
  • SPRO $5.00
  • OMCC N/A
  • AVG Volume (30 Days)
  • SPRO 218.6K
  • OMCC 1.3K
  • Earning Date
  • SPRO 05-14-2025
  • OMCC 02-14-2025
  • Dividend Yield
  • SPRO N/A
  • OMCC N/A
  • EPS Growth
  • SPRO N/A
  • OMCC N/A
  • EPS
  • SPRO N/A
  • OMCC N/A
  • Revenue
  • SPRO $47,977,000.00
  • OMCC $25,153,000.00
  • Revenue This Year
  • SPRO N/A
  • OMCC N/A
  • Revenue Next Year
  • SPRO N/A
  • OMCC N/A
  • P/E Ratio
  • SPRO N/A
  • OMCC N/A
  • Revenue Growth
  • SPRO N/A
  • OMCC N/A
  • 52 Week Low
  • SPRO $0.51
  • OMCC $5.29
  • 52 Week High
  • SPRO $1.72
  • OMCC $7.55
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 54.69
  • OMCC N/A
  • Support Level
  • SPRO $0.51
  • OMCC N/A
  • Resistance Level
  • SPRO $0.83
  • OMCC N/A
  • Average True Range (ATR)
  • SPRO 0.08
  • OMCC 0.00
  • MACD
  • SPRO 0.01
  • OMCC 0.00
  • Stochastic Oscillator
  • SPRO 76.85
  • OMCC 0.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About OMCC OLD MARKET CAPITAL CORPORATION

Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.

Share on Social Networks: